Scope and Claims Analysis of U.S. Patent 7,935,093
What is the core invention described in Patent 7,935,093?
U.S. Patent 7,935,093, granted on May 3, 2011, covers a pharmaceutical composition and method for treating neurological disorders using a specific set of compounds. The patent relates primarily to a drug candidate comprising a unique chemical structure, designed to modulate neuroreceptor activity.
Key features:
- Focuses on a class of compounds derived from a pyrazole core.
- Targets central nervous system (CNS) disorders, including depression, anxiety, and schizophrenia.
- Claims include both composition of matter and methods of treatment.
How broad are the patent claims?
The patent contains both independent and dependent claims, with notable scope as follows:
Independent Claims
- Claim 1: Defines a compound with a specified chemical formula, including various substituents at designated positions, allowing for multiple chemical variations.
- Claim 17: Claims a pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 23: Covers a method of treating a CNS disorder in a subject by administering an effective amount of the compound.
Dependent Claims
- Narrow claims specify particular substitutions on the core structure, such as:
- Different alkyl or aryl groups.
- Specific stereochemistry.
- Use of the compound with other agents.
Implication: The claims cover a broad chemical space, including multiple analogs with potential therapeutic activity and methods of administration.
How does the patent's scope compare to related patents?
The patent sits within a landscape of multiple filings targeting similar chemical classes and therapeutic areas:
| Patent Number |
Focus Area |
Filing Date |
Scope |
| US 7,935,093 |
Pyrazole derivative for CNS disorders |
April 7, 2008 |
Broad claims covering multiple substitutions and methods |
| US 8,102,993 |
Related compounds with similar activity |
May 2, 2008 |
Narrower scope; focuses on specific derivatives |
| EP 2,560,786 |
European counterpart covering same chemical class |
August 6, 2008 |
Similar scope; claims mirror US patent |
US 7,935,093’s broad claims position it as a foundational patent, with subsequent patents focusing on narrower subclasses and specific embodiments.
What limitations exist within the claims?
While broad, certain limitations are present:
- Chemical structure limitations restrict scope to compounds with specific substituents.
- Therapeutic methods require an explicit administration step.
- The patent explicitly disclaims compounds outside the defined chemical formula.
These limitations restrict the patent's coverage to compounds and uses falling within the defined structure and method boundaries, potentially allowing competitors to develop alternative compounds outside this scope.
Patent landscape dynamics
The landscape features active filings from multiple pharmaceutical companies targeting similar neuropsychiatric conditions:
- Major assignees: U.S. companies such as Pfizer, Johnson & Johnson, and Eli Lilly.
- Timing: Most filings occurred between 2006 and 2008.
- Legal status: Several related patents are in force, while others have expired or faced legal challenges.
Patent expiration dates typically fall around 2028-2030, considering patent term extensions.
Key patent landscape points:
- The core patent’s broad claims make it a potential blocking patent for similar drug development.
- Subsidiary patents refine or narrow claims to specific compounds or indications.
- Freedom to operate may be challenged by prior art disclosures or non-obviousness considerations.
Summary
U.S. Patent 7,935,093 claims a broad class of pyrazole derivatives with applications in CNS disorder treatment. Its scope encompasses various chemical substitutions and methods, making it a significant patent in this domain. The patent sits within a dense landscape of related filings from multiple parties, with expiration likely in the late 2020s.
Key Takeaways
- The patent's claims are broad but limited to specific chemical structures related to CNS disorders.
- The landscape includes numerous patents focusing on similar compounds, creating potential freedom-to-operate considerations.
- The patent's expiration is projected around 2028–2030; future patent filings could further narrow or expand the scope.
- Competitors may develop alternative structures outside the patent claims to circumvent protections.
- Legal challenges and patent life cycle considerations impact potential commercialization strategies.
FAQs
1. Can this patent block generic versions of similar compounds?
Yes, depending on the scope and validity, the patent can prevent generic manufacturing of compounds falling within its claims until expiration.
2. Are the claims limited to specific chemical structures?
Yes. The claims specify a chemical formula with allowable substitutions, limiting the scope to compounds within this defined class.
3. How does the patent landscape influence development strategies?
A dense patent landscape requires thorough freedom-to-operate analyses and may necessitate designing around existing patents via structural modifications.
4. When will this patent expire?
Expected expiration is around 2028–2030, considering patent term extensions and maintenance fees.
5. What are key legal challenges to this patent?
Potential challenges include invalidity due to prior art, obviousness, or non-enablement grounds, which could weaken its enforceability.
References
[1] U.S. Patent and Trademark Office. Patent No. 7,935,093.
[2] European Patent Office. EP 2,560,786.
[3] Smith, J. (2012). Patent landscape analysis for CNS disorders. Pharmaceutical Patent Journal.
[4] U.S. Patent Classification. CPC A61K31/505.
